| Project/Area Number |
26463049
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
TANAKA TAKUYA 熊本大学, 医学部附属病院, 診療助手 (30631767)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
尾木 秀直 熊本大学, 大学院生命科学研究部(医), 助教 (10315426)
篠原 正徳 熊本大学, 医学部附属病院, 非常勤診療医師 (90117127)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MASANORI Shinohara 熊本大学, 医学部附属病院, 非常勤診療医師 (90117127)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 転移 / Angptl4 / ANGPT4 / 口腔癌 / 遠隔転移 / NF-ｋB / 肺転移 |
|---|
| Outline of Final Research Achievements |
Background: Angptl4 is a critical mediator and promotes trans-endothelial migration of cancer cells．We found a marked increase of Angptl4 mRNA in tongue cancer cells that metastasized into the lung (Tanaka et al, Int. J. Oncol. 2016). Thus, we investigated a relationship between tongue cancer cell Angptl4 expression and clinicopathological parameters of the patients. Methods: Immunohistochemical staining for Angptl4 was performed for tongue cancer tissues from patients who had radical surgery but not pre-operative therapies. Twenty patients with metastasis and 20 patients without metastasis were enrolled. Results: By Kaplan-Meier method, Angptl4-positive patients showed significantly shorter overall survival and recurrence-free survival than Angptl4-negative patients. Conclusion: Angptl4 is likely associated with tongue cancer progression and its expression of the cancer cells may be predictive of poor prognosis of the patients. Thus, Angptl4 is a possible therapeutic target.
|
